Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| PolyBio Research Foundation | OTHER |
| The Anlyan Center | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai.
This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo.
This study aims to evaluate the efficacy of Sirolimus in adults with Long COVID. Efficacy will be evaluated by measuring patient-reported outcomes in response to Sirolimus.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Low-dose sirolimus | Experimental | Participants will follow the escalation scheme and receive sirolimus for up to 12 weeks. |
|
| Placebo | Placebo Comparator | Participants will follow the escalation scheme and receive the placebo for up to 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low-dose sirolimus | Drug | Participants will take sirolimus, at home, for 12 weeks (3 months).
|
| Measure | Description | Time Frame |
|---|---|---|
| European Quality of Life-Visual Analogue Scale (EQ-VAS) | The EQ VAS records the patient's self-rated health on a visual analogue scale where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0), with higher scores indicating better health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Measure | Description | Time Frame |
|---|---|---|
| The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L) | The EQ-5D-5L is a validated, standardized, generic instrument that is a preference-based health- related quality of life questionnaire. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Full scale from 5 to 25, with higher score indicating poorer health outcomes. |
Not provided
Inclusion Criteria:
Provision of signed and dated informed consent form
Any sex, aged 18+
Must be able to attend all study visits located at 5 East 98th St, New York, NY
Diagnosed with:
Long COVID
Documented clinical history of confirmed or suspected acute SARS-CoV-2 infection a minimum of 6 months prior to contact with the study team
Formal diagnosis of Long COVID from a physician
At least a six-month history of one of the following symptoms following SARSCoV-2 infection:
Exclusion Criteria:
Pre-existing conditions including, but not limited to:
Current use of sirolimus
Taking a medication with known interactions to sirolimus:
Febrile illness within the last 3 months of planned baseline evaluation
Treatment with another investigational drug or other investigational intervention within 3 months of planned baseline evaluation
Prophylactic use of aspirin (325 mg daily) for cardiovascular indications will be permitted in participants. All other medications for chronic medical conditions should be initiated at least two months prior to enrollment.
Uncontrolled diabetes, unstable ischemic heart disease, clinically significant underlying pulmonary disease, history of an immunodeficiency or receiving immunosuppressive therapy; history of coagulopathy or medication condition requiring long-term anticoagulation; history of hepatic impairment; taking angiotensin-converting enzyme (ACE) inhibitors
Participants who are planning to be or are pregnant
Participants who are nursing
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| David Putrino, PT, PhD | Contact | 212-241-7658 | coreresearch@mountsinai.org | |
| Mackenzie Doerstling, MPH | Contact | 212-241-7658 | coreresearch@mountsinai.org |
| Name | Affiliation | Role |
|---|---|---|
| David Putrino, PT, PhD | Icahn School of Medicine at Mount Sinai | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Recruiting | New York | New York | 10029 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000094024 | Post-Acute COVID-19 Syndrome |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D020123 | Sirolimus |
| ID | Term |
|---|---|
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Participants will take a matching placebo, at home, for 12 weeks (3 months).
|
|
| Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) | The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. The values of all item responses are averaged to generate subscores for each dimension. From these subscores, a global physical health score and a global mental health score are generated. The scores are translated into T-scores according to a reference population with a mean of 50 and a standard deviation of 10. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| General Symptom Questionnaire (GSQ-30) | The General Symptom Questionnaire-30 (GSQ-30) is a valid and reliable instrument to assess symptom burden among patients with acute and post-treatment. The GSQ-30 total score ranges from 0 to 120, with higher scores indicating a greater symptom burden. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Patient Health Questionnaire (PHQ-9) | The PHQ-9 is a series of questions assessing presence and severity of depression symptoms. It evaluates each of the DSM-IV depression criteria and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Full scale from 0-27, with higher score indicating more severe symptoms. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Generalized Anxiety Disorder (GAD-7) | The GAD-7 is a 7-item scale developed and validated to identify generalized anxiety disorder and its severity. It assesses the frequency of 7 anxiety symptoms and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). Total scores of 5, 10, and 15 correspond to mild, moderate, and severe generalized anxiety disorder, respectively. Full scale from 0-21, with higher score indicating more symptoms. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Neuro-QoL™ v2.0 Cognitive Function-Short Form | The Neuro-QoL Cognitive Function v2.0 short form assesses perceived difficulties in cognitive abilities, including memory, attention, decision making, planning, organizing, calculating, remembering, and learning. The short form consists of 8 questions assessed on a 5-point Likert scale, resulting in a raw score range of 8 to 40. A raw score is then converted to a T-score using conversion tables. Scores 0.5 - 1.0 SD worse than the mean (T-score 40-45) = mild symptoms/impairment. Scores 1.0 - 2.0 SD worse than the mean (T-score 30-40) = moderate symptoms/impairment. Scores 2.0 SD or more worse than the mean (T-score below 30) = severe symptoms/impairment. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Single-item Sleep Quality Scale (SQS) | The SQS is a visual analog scale that instructs respondents to rate their overall quality of sleep over a 7-day recall period from 0 to 10. Scores of 0, 1, 4, 7, and 10 correspond to terrible, poor, fair, good, and excellent, respectively. Higher scores indicate better sleep quality. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24)] |
| Fatigue Severity Scale | The Fatigue Severity Scale (FSS) uses a 7-point scale (1-7) to assess fatigue, with higher scores indicating greater severity, and a total score ranging from 9 to 63. Higher scores indicate more severe fatigue. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Fatigue Visual Analogue Scale [F-VAS]) | The F-VAS consists of 18 items related to fatigue and energy in a visual analogue scale from 0 to 100. A higher score indicates more fatigue. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| DePaul Post-Exertional Malaise Questionnaire (DSQ) | The DSQ is designed to evaluate 54 classic ME/CFS symptoms, including fatigue, post-exertional malaise, sleep, pain, neurological/cognitive impairments, and autonomic, neuroendocrine, and immune symptoms. Each symptom's frequency and intensity are rated on a 5-point scale (0-4). Frequency and severity scores are multiplied by 25, added together, and then divided by 2 to create a composite frequency/severity score for each symptom. These scores range from 0 to 100, with higher scores indicating a greater symptom burden. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Composite Autonomic Symptom Score 31(COMPASS-31) | The COMPASS-31 is a 31-question self-assessment instrument of autonomic symptoms and function that is up-to-date, broadly applicable, easy to administer in a short amount of time, and based on a scientific approach. The total score ranges from 0 to 100, with higher scores indicating greater autonomic dysfunction. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Pain (P-VAS) | Using a visual analogue scale, patients mark a point on a line representing a continuum from "no pain" to "worst pain," with scores ranging from 0 to 100, where higher scores indicate greater pain. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24)] |
| University of California-Los Angeles (UCLA) Loneliness Scale (3-item) | The UCLA Loneliness (3-item) Scale scores range from 3 to 9, with higher scores indicating greater perceived loneliness. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| Adapted Berkman-Syme Social Network/Connection Index | This is a self-report questionnaire used to assess social integration and isolation, focusing on marital status, frequency of contact, and participation in social activities, particularly relevant for older adults. Each item is scored on a scale from 1-4 where higher values reflect greater frequency (e.g., 4 = "5 or more times a week"). For each respondent, a sum score is calculated by adding the scores of all five items, yielding a possible score range of 5-25. Higher sum scores reflect higher levels of social connection and lower social isolation. | Baseline (Week 0) and Post-treatment (Week 12 and Week 24) |
| D007239 |
| Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |